Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 595

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 2
Chunk 595
---
2023

			720,909

			$
			19.51

			Expired

			(111,192
			)

			7.26

			Balance - September 30, 2024

			609,717

			$
			21.74

			Issued

			326,560

			3.45

			Expired

			(1,687
			)

			22.40

			Balance - September 30, 2025

			934,590

			$
			15.35

The weighted average contractual life remaining on the outstanding warrants at September 30, 2025 is 28 months.

The following table summarizes information about the warrants outstanding at September 30, 2025:

			Number of Warrants

			Exercise Prices 

			Expiry Dates

			173,614

			$
			10.50

			December 2025

			15,627

			$
			56.00

			February 2026

			27,399

			$
			31.94

			March 2027

			391,390

			$
			24.64

			September 2027

			326,560

			$
			3.45

			October 2029

			934,590

The fair value of warrants issued during the year ended September 30, 2025 were estimated using the Black-Scholes option valuation model using the following assumptions:

			Year Ended September 30, 2025

			Class A Pref Share

			Risk free interest rate

			4.14
			%

			Expected life (years)

			5

			Expected share price volatility

			91.24
			%

			Expected dividend yield

			0.00
			%

F-17

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 2025 and 2024

Share options

The Company adopted an Equity Incentive Compensation Plan in 2019 (the “2019 Plan”) administered by the independent members of the Board of Directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The